Pipeline

A pipeline innovated by the global human crisis

Indivior is pioneering the development and discovery of non-opioid treatment strategies for OUD, as well as exploring new therapies to potentially address the needs of people suffering from alcohol, stimulant and cannabis use disorders. 

Indivior’s R&D has led to a range of daily and monthly treatment options for patients with moderate-to -severe opioid use disorder. We also developed a monthly treatment option for the treatment of schizophrenia in adult patients. 

Indivior’s quarterly R&D and pipeline update can be found here.

 

 

Preclinical

Phase 1

Phase 2

Phase 3

Regulatory Approval

Commercial Launch

 
 
 
 
 
 
 
  •  
    Treatment for Opioid Use Disorder

    Buprenorphine sublingual (SL) tablets

  •  
    Treatment for Opioid Use Disorder

    Buprenorphine and naloxone SL tablets

  •  
    Treatment for Opioid Use Disorder

    Buprenorphine and naloxone SL film

  •  
    Treatment for Opioid Use Disorder

    RBP-6000 Buprenorphine extended-release injection for subcutaneous use

  •  
    Treatment for Schizophrenia

    RBP-7000 Risperidone XR injection for subcutaneous use

  •  
    Treatment for Opioid Overdose Rescue

    OPNT-003 opioid receptor antagonist nalmefene nasal spray

  •  
    Treatment for Alcohol Use Disorder

    INDV-4002§ opioid receptor antagonist naltrexone nasal spray

  •  
    Treatment for Acute Cannabinoid Overdose

    INDV-5004@ cannabinoid-1 receptor antagonist

  •  
    Treatment of Cannabis Use Disorder

    AEF0117* Cannabinoid-1 receptor synthetic signaling specific inhibitor

  •  
    Treatment for Substance Use Disorder

    INDV-2000** selective orexin-1 receptor antagonist

  •  
    Treatment for Substance Use Disorder

    INDV-1000*** Gamma-aminobutyric acid subtype B (GABAB) positive allosteric modulator (PAM)